This newspaper (reporter Yang Xiaojing).With the improvement of China's economic level and the change of population structure, the people's demand for high-quality medical services and health products is growing, and China's health industry is ushering in a period of rapid development. However, while developing rapidly, there is still a gap between China's health industry and developed countries in Europe and the United States. In this regard, during the two sessions of the National People's Congress, Lu Qingguo, a representative of the National People's Congress and chairman of Chenguang Biotechnology, suggested promoting the sustainable development of the health industry.
There is still a lot of room for improvement in China's health industry. Lu Qingguo pointed out that the proportion of the added value of China's health industry in GDP is lower than the general level of developed countries in Europe and the United States; The level of innovation and R&D of related enterprises is insufficient, and the phenomenon of low-level repeated production and imitation is still obvious; The resources of the industrial chain are scattered, there is a lack of effective synergy, most of the enterprises are small in scale, the system integration ability is insufficient, and the number of leading enterprises and their influence are limited.
Lu Qingguo suggested that we should continue to optimize the industrial environment, provide more industrial policies, and promote the rapid and sustainable development of the health industry.
The first is to encourage upstream and downstream enterprises or cross-industry enterprises to cooperate in multiple forms, create a centralized exhibition model of the health industry, and form a synergistic effect, especially to support and cultivate potential leading enterprises, so as to make them the core force leading the development of the industry.
The second is to encourage enterprises to strengthen R&D investment, enhance innovation capabilities, especially in basic research such as raw materials, efficacy, and clinical practice, and promote the high-quality development of the industry. Local governments can consider setting up special policies or tax incentives to support the listing of high-quality innovative products such as health foods and formula foods for special medical purposes, so as to increase the motivation for enterprises to carry out innovation activities.
The third is to strengthen the construction of industry standardization, promote and support enterprises to participate in the formulation and improvement of industry standards, guide and standardize the development of the industry through standards, and improve product quality.